Regeneron to Showcase Progress from Innovative Oncology
Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be...
Source: globenewswire.com
Mark Awad News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Awad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Awad Today - Breaking & Trending Today
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ubamatamab (MUC16xCD3) in recurrent ovarian cancer also to be presented Additional presentations on outcomes of Libtayo-based therapy in advanced non-small cell lung cancer, including PD-L1 expression and histology specific subgroups TARRYTOWN, N.Y., Oct. 15,
Source: yahoo.com
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
16.10.2023 - Event-free survival of investigational use of Libtayo (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ...
Source: wallstreet-online.de
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotoras
Avutometinib + Sotorasib Combination Demonstrated Preliminary Efficacy with Confirmed Responses in both KRAS G12C Inhibitor Resistant and Naïve PatientsNo New Safety Signals Observed in Combination; Most Treatment-Related Adverse Events Mild to ModerateEnrollment of Patients Naïve to or Previously Treated with a KRA...
Source: pharmiweb.com
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
First presentation of results from CheckMate -901 show survival benefit with Opdivo + chemotherapy in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma who...
Source: marketscreener.com